Latest in Finance

GSK to pay up to $750m for T-Cell cancer drug from Chinese biotech Chimagen Biosciences

The company has agreed to acquire a potential best-in-class trispecific T-cell engager with the aim of developing and commercialising it for multiple myeloma, with Phase I trials expected in 2027

Find out more
GSK to pay up to $750m for T-Cell cancer drug from Chinese biotech Chimagen Biosciences

NIS and Proteos launch TrueCourse Biosciences to support AI drug discovery

NIS and Proteos launch TrueCourse Biosciences to support AI drug discovery

NanoImaging Services and Proteos have launched TrueCourse Biosciences, combining protein production, structural biology and biophysical analysis to support experimental...
See more
OutSee secures £50,000 Innovate UK grant for agentic AI drug target validation pilot

OutSee secures £50,000 Innovate UK grant for agentic AI drug target validation pilot

OutSee will use Innovate UK and Empirical Ventures funding to develop an agentic AI sub-system designed to accelerate initial validation of drug targets identified by its predictive genomics platform, Nomaly
Onyx Scientific invests £1.5m into Sunderland API plant

Onyx Scientific invests £1.5m into Sunderland API plant

The expansion brings the site to ten GMP suites by Q1 2027, increasing concurrent capacity for commercial API production and accelerating early-phase programmes — as well as creating nine immediate roles in production chemistry, analytical and QA
PerkinElmer acquires SimoTech to expand pharma manufacturing automation

PerkinElmer acquires SimoTech to expand pharma manufacturing automation

The acquisition strengthens PerkinElmer’s pharmaceutical services offering with SimoTech’s expertise in manufacturing automation, digital manufacturing and GMP IT systems
Novartis signs up to $3.2bn Alteogen deal for subcutaneous drug delivery

Novartis signs up to $3.2bn Alteogen deal for subcutaneous drug delivery

The agreement gives Novartis options to develop and commercialise multiple subcutaneous products using Alteogen’s ALT-B4 hyaluronidase technology
Lilly to acquire Merida Biosciences for up to $2.875bn

Lilly to acquire Merida Biosciences for up to $2.875bn

Eli Lilly is acquiring Merida Biosciences in a deal worth up to $2.875bn to expand its pipeline of precision therapies for autoimmune and allergic diseases
Fulcrum Therapeutics merges with Slate Medicines in $245m-backed deal

Fulcrum Therapeutics merges with Slate Medicines in $245m-backed deal

The all-stock merger sees Fulcrum rebuild following its pociredir discontinuation, with the combined entity focusing on SLTE-1009 — a monoclonal antibody in development for migraine and headache disorders — funded into 2029
Prescient completes integration of Uptake and Dolon under single global brand

Prescient completes integration of Uptake and Dolon under single global brand

Prescient Healthcare Group has completed the integration of Uptake and Dolon, creating a 550-strong life sciences consultancy spanning commercial strategy, medical affairs, competitive intelligence and market access
From Indonesia to the world: support Beta Pharmacon’s manufacturing excellence with GEA granulation technology

From Indonesia to the world: support Beta Pharmacon’s manufacturing excellence with GEA granulation technology

By integrating GEA granulation technology into its new facility, Beta Pharmacon has enhanced process control, reinforced its commitment to regulatory compliance, and secured GMP and USP qualifications to supply essential micronutrient supplements

Latest posts in Finance

Faller Packaging acquires Greek pharma packaging firm Paperpack

Faller Packaging acquires Greek pharma packaging firm Paperpack

Faller Packaging has acquired pharmaceutical packaging specialist Paperpack, expanding its European network and strengthening its presence in South-Eastern Europe
AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes

AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes

The payment — comprising $7m in licence fees and $5m direct investment — kicks off a collaboration worth more than $2.2bn in potential milestones, with QuantumCell assuming global rights to ACD856 and the NeuroRestore platform
DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction

DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction

The pair will combine DNA Script's EDS technology with GE HealthCare's DNA scaling technology to create a faster, more flexible manufacturing process for cell-free DNA as the use of personalised and time-sensitive genetic medicines grows
Ratio Therapeutics raises $70m to expand radiopharmaceutical manufacturing

Ratio Therapeutics raises $70m to expand radiopharmaceutical manufacturing

The Series C financing will support clinical development of Ratio’s Ac-225 radiotherapeutic pipeline and expansion of its radiopharmaceutical manufacturing infrastructure
You need to be a subscriber to read this article.
Click here to find out more.
AstraZeneca-BMS $400bn merger could reshape US pharma manufacturing

AstraZeneca-BMS $400bn merger could reshape US pharma manufacturing

A potential AstraZeneca acquisition of Bristol Myers Squibb would create a near-$400bn pharma giant, combining major oncology portfolios and extensive US manufacturing operations
Clean Cells expands biopharma analytics with Anaquant acquisition

Clean Cells expands biopharma analytics with Anaquant acquisition

The purchase adds mass spectrometry-based protein characterisation and HCP analysis to Clean Cells’ GMP testing platform, creating an end-to-end analytical offering for biologics developers
Qureight raises $20m Series B to expand AI imaging platform into asthma, pulmonary hypertension and bronchiectasis

Qureight raises $20m Series B to expand AI imaging platform into asthma, pulmonary hypertension and bronchiectasis

The Molten Ventures-led round funds a 3D chest imaging Foundation Model laboratory and commercial expansion, building on Qureight's established lung fibrosis CRO capabilities across a $27.5bn clinical trials market.
Celonic and Leukocare to help clients with complex biologics and advanced drug product profiles

Celonic and Leukocare to help clients with complex biologics and advanced drug product profiles

Celonic and Leukocare partner to combine bioprocessing and GMP manufacturing with data-driven formulation expertise for complex biologics
ProBioGen and VarmX announce collaboration for advanced cell line development

ProBioGen and VarmX announce collaboration for advanced cell line development

This partnership builds upon ProBioGen's extensive expertise in coagulation factor development, including successful programmes with Factor VII and Factor VIII therapeutics
Mechitronic acquires Lambert to strengthen pharma and medtech assembly platform

Mechitronic acquires Lambert to strengthen pharma and medtech assembly platform

The €20m deal adds Lambert's 50-year complex assembly and filling automation expertise in Tadcaster to Mechitronic's 15-brand network, strengthening the group's UK pharma presence as it targets €285m aggregate revenue
Samsung Biologics to acquire PolyPeptide in $1.8bn deal

Samsung Biologics to acquire PolyPeptide in $1.8bn deal

The manufacturer is set to acquire peptide CDMO PolyPeptide for CHF 1.46bn, expanding its manufacturing capabilities into peptide APIs and strengthening its global footprint across the US, Europe and India

Sponsor content

Samsung Biologics signs USD 262 million manufacturing agreement with European pharmaceutical company

Samsung Biologics signs USD 262 million manufacturing agreement with European pharmaceutical company

Long-term agreement extends manufacturing commitments through 2033 and takes cumulative contract value beyond USD 21.9 billion
Gerresheimer reports slight revenue growth in Q1 2026 and a strong focus on free cash flow

Gerresheimer reports slight revenue growth in Q1 2026 and a strong focus on free cash flow

Preliminary results: Revenues of 524 million EUR, adjusted EBITDA of 66 million EUR; stronger second half of the year expected
Digitalisation: more space for research and development in Salzburg, Austria

Digitalisation: more space for research and development in Salzburg, Austria

COPA-DATA is investing €15 million in the project, underlining its long-term commitment to Salzburg and Austria as a location for technology, research and innovation
Gerresheimer is selling Centor and its global Primary Packaging Plastics business to Apax Funds

Gerresheimer is selling Centor and its global Primary Packaging Plastics business to Apax Funds

Significant optimisation of the capital and financing structure through expected cash inflows, meaningfully decreasing leverage
LogiPharma Digital Supply Chain Connect announces 2026 agenda for pharma supply chain summit

LogiPharma Digital Supply Chain Connect announces 2026 agenda for pharma supply chain summit

Exclusive Frankfurt event to bring together senior pharma supply chain leaders, digital transformation specialists and technology partners
Lonza and Engitix announce license agreement to advance targeted ADC Development

Lonza and Engitix announce license agreement to advance targeted ADC Development

Lonza grants Engitix target-specific license for GlycoConnect, HydraSpace and SYNtecan E linker-payload technologies for ADC development
Gerresheimer publishes 2025 annual and consolidated financial statements

Gerresheimer publishes 2025 annual and consolidated financial statements

Stable revenue in a challenging financial year
Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe

Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe

After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia. Production capacity...
Almac group delivers record year of growth

Almac group delivers record year of growth

Revenue rises to £1.1 billion as profit increases 16% and workforce expands to more than 7,900 amid continued global investment programme
Andelyn Biosciences launches LVV Curator platform, bringing proven viral vector platform pedigree to Lentiviral Vector manufacturing for cell therapies

Andelyn Biosciences launches LVV Curator platform, bringing proven viral vector platform pedigree to Lentiviral Vector manufacturing for cell therapies

New platform leverages the established Curator platform methodology to industrialise Lentivirus processes from concept to clinic
Adragos Pharma appoints Kostas Rengis as Chief Executive Officer

Adragos Pharma appoints Kostas Rengis as Chief Executive Officer

Munich, Germany – May 7th, 2026 – Adragos Pharma, a global contract development and manufacturing organisation (CDMO), today announced the appointment of Konstantinos...
Syngene strengthens leadership team with two key appointments to support next phase of growth

Syngene strengthens leadership team with two key appointments to support next phase of growth

Abhijit Zutshi joins as CCO and Maninder Kapoor Puri as CHRO. India/U.S./UK, 1 May 2026: Syngene International, a global contract research, development, and manufacturing...